Study of takhzyro (lanadelumab) for teens and adults with HAE in Saudi Arabia
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study looks at how well Takhzyro (lanadelumab) works for people with a specific type of hereditary angioedema (HAE) that is caused by a C1 inhibitor deficiency. It is for teenagers and adults who have already been taking Takhzyro for at least 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years or older when you started taking Takhzyro.
- You must have been diagnosed with HAE type 1 or type 2 (caused by C1 inhibitor deficiency).
- You must have been taking Takhzyro continuously for at least 6 months.
- You cannot have other forms of HAE (like type 3) or normal C1 inhibitor function.
- You must have complete medical records from when you started Takhzyro and after 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study watches how well Takhzyro works for people 12 and older with hereditary angioedema (HAE) in South Korea. It's for those already using or about to start Takhzyro as prescribed by their doctor.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study looks at how people with hereditary angioedema (HAE) are diagnosed and treated in Egypt. It may help doctors better understand and care for this condition.
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
This study tests a long-term daily pill to prevent swelling attacks in people with hereditary angioedema (HAE). The pill, called deucrictibant, is designed to block a protein involved in causing attacks. It's for adolescents and adults who want to reduce how often swelling episodes occur.
This study is for people who already finished a previous trial of the drug ADX-324 for hereditary angioedema. It tests the long-term safety and effectiveness of continuing the medication.
Hear when a new Hereditary Angioedema (HAE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.